| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y203-02013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate |
2012-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101470087-B1 |
| titleOfInvention |
Composition for preventing or treating or improvingatopic dermatitis comprising immunosuppressant and transglutaminase 2 inhibitor |
| abstract |
The present invention relates to a composition for the prevention, treatment or amelioration of atopic dermatitis comprising an immunosuppressant and a transglutaminase inhibitor as an active ingredient. The combination administration of the immunosuppressant and transglutaminase inhibitor according to the present invention , The dose of the immunosuppressant agent which is difficult to be administered for a long time due to side effects and which is susceptible to worsening of the lesion at the time of discontinuation at the time of discontinuation is decreased and the transglutaminase inhibitor which has little effect on atopy treatment in some patients is mixed with the immunosuppressant, A much higher therapeutic effect can be achieved than the single administration of an immunosuppressant or a transglutaminase second inhibitor. |
| priorityDate |
2011-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |